Saram ConsultingGxP & AI Consulting for Life Sciences. Custom AI integrations, Part 11 compliance validation, and equity-based engineering partnerships for biotech.Explore Services at saram.io →
← Back to Home

Alebund Pharmaceuticals

Private
#Renal Disease#IgA Nephropathy#Chronic Kidney Disease

Biopharma developing innovative therapies for renal diseases including CKD, IgA nephropathy, diabetic kidney disease, and hyperphosphatemia.

Company Info

Sector:Small Molecule Pharma
Headquarters:Shanghai, China
Founded:2017
Website:http://www.alebund.com/

Upcoming Milestones & Key Dates

2026-Q4
Clinical

AP308 IgA Nephropathy Phase 2 data readout

2027-Q1
Regulatory

AP306 NDA filing expected

Clinical Development Pipeline

AP308

Target: Complement system
IgA Nephropathy
Preclinical
Phase 1
Phase 2
Phase 3
Approved

AP306

Target: Phosphate binder
Hyperphosphatemia
Preclinical
Phase 1
Phase 2
Phase 3
Approved

AP301

Target: SGLT2 inhibitor
Diabetic Kidney Disease
Preclinical
Phase 1
Phase 2
Phase 3
Approved

Recent News

Leadership Team

Gavin Xia

CEO

Careers & Job Openings

See all open roles

Various
Shanghai, China
Apply Now →